LifeVantage Raises Fiscal 2025 Revenue Forecast Amid Strong Sales

2025-01-09 companies

Sandy, Utah, Thursday, 9 January 2025.
LifeVantage Corporation increased its fiscal 2025 revenue forecast to $235-245 million, reflecting a 31% revenue growth in Q2 and strengthening its market position.

Strong Q2 Performance Drives Optimistic Outlook

LifeVantage Corporation (Nasdaq: LFVN), a Utah-based nutraceutical company, announced on January 8, 2025, that its second-quarter revenue reached approximately $67.5 million, marking a significant 31 percent increase year-over-year and a 43 percent sequential increase from Q1 fiscal 2025 [1][2]. This exceptional performance has led the company to raise its fiscal 2025 revenue guidance from the previous $200-210 million range to an updated forecast of $235-245 million [1][3].

Market Growth and Customer Base Expansion

The company has demonstrated remarkable growth in its active accounts, particularly in the Americas region, where it achieved a 22.7 percent year-over-year increase and a 25.4 percent sequential growth from Q1 fiscal 2025 [2]. Globally, active accounts grew by 12.1 percent compared to the previous year [2]. According to Steve Fife, President and CEO of LifeVantage, this success is largely attributed to the strong sales performance of their MindBody GLP-1 System™, which was launched in October [6].

Product Portfolio and Market Position

LifeVantage maintains a diverse portfolio of health and wellness products, including its flagship Protandim® line, TrueScience® Liquid Collagen, and AXIO® nootropic energy drinks [2][6]. The company’s business model combines direct-to-consumer sales with independent consultants, focusing on nutrigenomic activators and dietary supplements [1]. The company, founded in 2003 and headquartered in Lehi, Utah, has established a presence in multiple international markets, including Mexico, Japan, Australia, and several European countries [1].

Financial Outlook and Future Plans

Investors can expect detailed fiscal Q2 results, including comprehensive profitability metrics, in early February 2025 [2][6]. The company’s recent performance suggests a strong market position, with the highest enrollment figures recorded since Q3 fiscal 2019 [6]. This positive trajectory in both revenue and active accounts indicates potential for continued growth and increased shareholder value in the coming quarters [2][6].

Sources

revenue forecast LifeVantage